Drug intelligence / Profile preview

PRV131

Development stage: Phase 3
Lead developer: Privo Technologies
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intratumoral

Overview

PRV131 is a nanoengineered intratumoral injectable suspension developed by Privo Technologies for the treatment of solid tumors, with a primary focus on oral squamous cell carcinoma (OSCC). The drug utilizes Privo's proprietary PRV Platform to deliver a highly concentrated polymeric nanoparticle suspension of cisplatin directly into the tumor. This delivery system is designed to provide sustained drug release (lasting over 28 days) and achieve high local concentrations while minimizing systemic exposure and associated toxicities. PRV131 is currently being evaluated as a neoadjuvant therapy to debulk tumors prior to surgery in patients with T1-T3 oral cavity cancer, aiming to improve surgical outcomes and preserve oral tissue.

Other names: PRV-131PRV131PRV 131

Targets

DNA

Beyond the preview

Go deeper on PRV131.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRV131.

Explore the full profile